Literature DB >> 26670214

CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Catherine A Wassenaar1, Qian Zhou1, Rachel F Tyndale2.   

Abstract

CYP2A6 genotyping is of clinical importance--CYP2A6 gene variants influence nicotine metabolism and are associated with nicotine dependence, cigarettes per day, smoking cessation and the risk for tobacco-associated cancers. CYP2A6 gene variants also influence the metabolism of therapeutic drugs, such as the anticancer agents, tegafur and letrozole. Over the years, CYP2A6 genotyping methods have evolved to incorporate novel gene variants and to circumvent genotyping errors resulting from the high degree of homology between CYP2A6 and neighboring CYP2A genes. Herein, CYP2A6 genotyping strategies are described for commonly genotyped functionally significant alleles including SNPs, small insertions/deletions and more complex structural variants. The methods presented utilize higher throughput SYBR green real-time PCR technology in addition to standard thermocycling.

Entities:  

Keywords:  CYP2A6; SNP; end point PCR; gene deletion; hybrid allele; real-time PCR

Mesh:

Substances:

Year:  2015        PMID: 26670214      PMCID: PMC4712027          DOI: 10.2217/pgs.15.156

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  54 in total

Review 1.  Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19.

Authors:  S M Hoffman; D R Nelson; D S Keeney
Journal:  Pharmacogenetics       Date:  2001-11

2.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

3.  In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.

Authors:  Sompop Peamkrasatam; Kampon Sriwatanakul; Kazuma Kiyotani; Masaki Fujieda; Hiroshi Yamazaki; Tetsuya Kamataki; Krongtong Yoovathaworn
Journal:  Drug Metab Pharmacokinet       Date:  2006-12       Impact factor: 3.614

4.  3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression.

Authors:  Jue Wang; Mariá Pitarque; Magnus Ingelman-Sundberg
Journal:  Biochem Biophys Res Commun       Date:  2005-12-19       Impact factor: 3.575

5.  CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populations.

Authors:  Catherine A Wassenaar; Yuanqing Ye; Qiuyin Cai; Melinda C Aldrich; Joanne Knight; Margaret R Spitz; Xifeng Wu; William J Blot; Rachel F Tyndale
Journal:  Carcinogenesis       Date:  2014-11-21       Impact factor: 4.944

6.  Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35).

Authors:  Songhee Han; Seunghye Choi; Young-Jin Chun; Chul-Ho Yun; Chang Hoon Lee; Hee Jung Shin; Han Sung Na; Myeon Woo Chung; Donghak Kim
Journal:  Biol Pharm Bull       Date:  2012       Impact factor: 2.233

7.  Chipping away at the genetics of smoking behavior.

Authors:  Christopher I Amos; Margaret R Spitz; Paul Cinciripini
Journal:  Nat Genet       Date:  2010-05       Impact factor: 38.330

8.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.

Authors:  Noritaka Ariyoshi; Masami Miyamoto; Yuri Umetsu; Hideo Kunitoh; Hirotoshi Dosaka-Akita; Yu-Ichi Sawamura; Jun Yokota; Nobuo Nemoto; Kunio Sato; Tetsuya Kamataki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-09       Impact factor: 4.254

9.  CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.

Authors:  Matthew J Binnington; Andy Z X Zhu; Caroline C Renner; Anne P Lanier; Dorothy K Hatsukami; Neal L Benowitz; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2012-06       Impact factor: 2.089

10.  Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).

Authors:  Kazuma Kiyotani; Hiroshi Yamazaki; Masaki Fujieda; Shunsuke Iwano; Keiko Matsumura; Soisungwan Satarug; Pailin Ujjin; Tsutomu Shimada; F Peter Guengerich; Andrew Parkinson; Goro Honda; Kazuko Nakagawa; Takashi Ishizaki; Tetsuya Kamataki
Journal:  Pharmacogenetics       Date:  2003-11
View more
  13 in total

1.  Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity.

Authors:  Ahmed El-Boraie; Taraneh Taghavi; Meghan J Chenoweth; Koya Fukunaga; Taisei Mushiroda; Michiaki Kubo; Caryn Lerman; Nicole L Nollen; Neal L Benowitz; Rachel F Tyndale
Journal:  Addict Biol       Date:  2019-02-27       Impact factor: 4.280

2.  Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Authors:  Julie-Anne Tanner; Andy Z Zhu; Katrina G Claw; Bhagwat Prasad; Viktoriya Korchina; Jianhong Hu; HarshaVardhan Doddapaneni; Donna M Muzny; Erin G Schuetz; Caryn Lerman; Kenneth E Thummel; Steven E Scherer; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2018-01       Impact factor: 2.089

Review 3.  Preparing the Way: Exploiting Genomic Medicine to Stop Smoking.

Authors:  Laura J Bierut; Rachel F Tyndale
Journal:  Trends Mol Med       Date:  2018-01-04       Impact factor: 11.951

4.  Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors.

Authors:  Julie-Anne Tanner; Bhagwat Prasad; Katrina G Claw; Patricia Stapleton; Amarjit Chaudhry; Erin G Schuetz; Kenneth E Thummel; Rachel F Tyndale
Journal:  J Pharmacol Exp Ther       Date:  2016-11-04       Impact factor: 4.030

5.  Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.

Authors:  Meghan J Chenoweth; Jennifer J Ware; Andy Z X Zhu; Christopher B Cole; Lisa Sanderson Cox; Nikki Nollen; Jasjit S Ahluwalia; Neal L Benowitz; Robert A Schnoll; Larry W Hawk; Paul M Cinciripini; Tony P George; Caryn Lerman; Joanne Knight; Rachel F Tyndale
Journal:  Addiction       Date:  2017-11-02       Impact factor: 6.526

6.  Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations.

Authors:  Katrina G Claw; Julie A Beans; Seung-Been Lee; Jaedon P Avey; Patricia A Stapleton; Steven E Scherer; Ahmed El-Boraie; Rachel F Tyndale; Deborah A Nickerson; Denise A Dillard; Kenneth E Thummel; Renee F Robinson
Journal:  Nicotine Tob Res       Date:  2020-05-26       Impact factor: 4.244

7.  Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.

Authors:  Stephani L Stancil; Robin E Pearce; Rachel F Tyndale; Gregory L Kearns; Carrie A Vyhlidal; J Steven Leeder; Susan Abdel-Rahman
Journal:  Br J Clin Pharmacol       Date:  2019-03-12       Impact factor: 4.335

8.  Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.

Authors:  Julie-Anne Tanner; Jeffrey A Henderson; Dedra Buchwald; Barbara V Howard; Patricia Nez Henderson; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

9.  Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity.

Authors:  Neal L Benowitz; Gideon St Helen; Delia A Dempsey; Peyton Jacob; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2016-07       Impact factor: 2.089

10.  Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers.

Authors:  Evangelia Liakoni; Gideon St Helen; Delia A Dempsey; Peyton Jacob; Rachel F Tyndale; Neal L Benowitz
Journal:  Drug Alcohol Depend       Date:  2019-08-30       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.